Clinical trials: Hair Diseases
Hair Thinning
Efficacy and Tolerability of a Scalp Serum
The goal of this clinical trial is to evaluate the efficacy and tolerability of a scalp serum on 60 healthy females aged 25 to 65 years with Fitzpatrick skin phototypes I-VI and with mild to moderate thinning hair.
- Trial name
- NCT07500623
- Testing
- Scalp Serum
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Revision Skincare
Hair Thinning
Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth using XVIE solution applied on the scalp of women with self-perceived thinning hair. The main aims of this trial are: 1.
- Trial name
- NCT07221773
- Testing
- XVIE
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Trichotillomania
Feasibility Study for Treating Trichotillomania With Wearable Device and App System
Trichotillomania is characterized by recurrent hair pulling resulting in hair loss causing significant distress and impairment which persists despite repeated attempts to stop.
- Trial name
- NCT04241120
- Testing
- Device and app system designed for participant to self-administer Habit Reversal Training, Reminder bracelet control condition
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- HabitAware Inc.
Alopecia, Canities
6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair
This will be a 6-month randomized, double-blind, placebo-controlled trial. A total of 152 participants with hair loss, including some with gray hair, will be enrolled and randomly assigned to four groups.
- Trial name
- NCT06998680
- Testing
- VitaGreen Capsule A+VitaGreen Tonic, VitaGreen Capsule B+VitaGreen Tonic
- Where
- China
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Vita Green Pharmaceutical (H.K.) Ltd.
Androgenetic Alopecia
A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers
This exploratory phase IIa, double blind, randomized, vehicle controlled, multicenter dose-finding trial will evaluate the safety, tolerability, and efficacy of FOL-005 topical formulation (at 0.1%, 0.5% and 1.5% strength)…
- Trial name
- NCT04774874
- Testing
- Topical formulation
- Where
- Germany
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Follicum AB
Alopecia Areata
A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects
This first in human phase 1 study to Study will evaluate safety, tolerability, and pharmacokinetics of Single Ascending dose (SAD), Food effect (FE) and Multiple ascending dose (MAD) of OR-101 Administered Orally in healthy…
- Trial name
- NCT06045624
- Testing
- OR-101 (Single ascending dose), OR-101 (Food effect), OR-101 (Multiple ascending dose)
- Where
- Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Ornovi, Inc.
Alopecia Areata
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AA1 (NCT04518995)
- Testing
- CTP-543
- Where
- 72 sites in United States, Canada and 3 more
- Volunteers
- 706 people
- Sponsor
- Concert Pharmaceuticals
Alopecia, Androgenetic
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia
- Trial name
- NCT05802173
- Testing
- TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- Technoderma Medicines Inc.
Hypertrichosis
Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair
The purpose of this randomized, controlled, open-label pilot study is to evaluate the safety and efficacy of a novel intense pulsed light (IPL) device for removal of unwanted fine body hair.
- Trial name
- NCT01912950
- Testing
- Prowave LX IPL
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Alopecia
A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
This is a multicentre, open-label study to assess the safety, tolerability, and efficacy of 0.5 mg Dutasteride administered once daily for 52 weeks in men with Androgenetic Alopecia types III vertex, IV and V per the…
- Trial name
- NCT01831791
- Testing
- Dutasteride 0.5 mg
- Where
- 5 sites in Japan
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Androgenic Alopecia, Healthy Adult Male
Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia
The goal of this clinical trial is to evaluate the efficacy and safety of two different formulations of a food supplement on hair health in healthy Caucasian male subjects aged 35 to 65 years with mild to moderate androgenetic…
- Trial name
- NCT07806474
- Testing
- formulation of green tea leaf extract, bamboo shoot extract and selenium-enriched yeast, formulation of grape seed extract, bamboo shoot extract and selenium-enriched yeast
- Where
- 6 sites in Italy
- Volunteers
- 99 people
- Sponsor
- Activ'inside
Androgenetic Alopecia, Androgenic Alopecia
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss
To demonstrate that the ALRV5XR multi-molecular targeting treatment regimen of a daily shampoo, conditioner, topical serum and oral supplement is superior to placebo in promoting hair growth as assessed by change in hair density…
- Conditions
- Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair
- Trial name
- REBOOT-MEN (NCT04450589)
- Testing
- ALRV5XR, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Arbor Life Labs
Hair Thinning
The Effects of an Oral Hair Supplement on Hair Density, Growth, and Microbiome
The purpose of this study is to assess how an oral herbal supplement influences hair density, shine, growth, and microbiome.
- Trial name
- NCT06146166
- Testing
- Oral herbal supplement
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research
Alopecia Areata
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study.
- Trial name
- AA (NCT05255237)
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Androgenetic Alopecia
Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia
This study will be a single center, open-label study of a single concentration of ANR- 001.1. The solution will be applied to the scalp of 14 male subjects by study staff once daily for 7 days.
- Trial name
- NCT05864885
- Testing
- Minoxidil
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Aneira Pharma, Inc.
Androgenic Alopecia
Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia
An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects with Androgenic Alopecia.
- Trial name
- NCT02824380
- Testing
- DA-4001 H, DA-4001 L
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Dong-A ST Co., Ltd.
Alopecia
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
- Trial name
- NCT02781311
- Testing
- Setipiprant, Finasteride
- Where
- 18 sites in United States
- Volunteers
- 169 people
- Sponsor
- Allergan
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)
The purpose of the the study is to evaluate the ability of injections of Ji Gami(TM) C to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451151
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Alopecia Areata
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.
- Trial name
- NCT05522556
- Testing
- Ritlecitinib
- Sponsor
- Pfizer
Alopecia, Male Pattern Hair Loss
To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia
The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.
- Trial name
- NCT05218642
- Testing
- KX- 826 dosed at 2.5mg, KX-826 dosed at 5mg
- Where
- 10 sites in United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,